Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;101(6):1570-3.
doi: 10.1111/j.1349-7006.2010.01563.x. Epub 2010 Mar 15.

Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate

Norio Nonomura  1 , Hitoshi Takayama, Atsunari Kawashima, Masatoshi Mukai, Akira Nagahara, Yasutomo Nakai, Masashi Nakayama, Akira Tsujimura, Kazuo Nishimura, Katsuyuki Aozasa, Akihiko Okuyama
Affiliations

Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate

Norio Nonomura et al. Cancer Sci. 2010 Jun.

Abstract

Macrophage scavenger receptor (MSR)-positive inflammatory cells and tumor-associated macrophages (TAMs) have been reported to regulate the growth of various cancers. In this study, the infiltration of MSR-positive cells and TAMs was analyzed to predict the outcome of repeat biopsy in men diagnosed as having no malignancy at the first prostate biopsy. Repeat biopsy of the prostate was carried out in 92 patients who were diagnosed as having no malignancy at the first biopsy. Of these, 30 patients (32.6%) were positive for prostate cancer at the repeat biopsy. Tumor-associated macrophages and MSR-positive cells were immunohistochemically stained with mAbs CD68 and CD204, respectively. Six ocular measuring fields were chosen randomly under a microscope at x400 power in the initial negative biopsy specimens, and the mean TAM and MSR counts for each case were determined. No difference in TAM count was found between the cases with or without prostate cancer. By contrast, the MSR count in patients with cancer was significantly lower than that in patients without cancer at the repeat biopsy (P < 0.001). Logistic regression analysis indicated that the MSR count at first biopsy is a significantly better predictive factor for positive repeat biopsy than PSA velocity, interval between first and repeat biopsies, or TAM count. Decreased infiltration of MSR-positive cells in negative first biopsy specimens was correlated with positive findings in the repeat biopsy. The MSR count might be a good indicator for avoiding unnecessary repeat biopsies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative immunostaining for macro‐phage scavenger receptor (MSR) cells from men who underwent repeat biopsy of the prostate. Representative cases with low (A) and high (B) MSR counts are shown. Arrowheads indicate MSR‐positive cells.
Figure 2
Figure 2
Association between the final pathological results and the serum prostate‐specific antigen level at the first (A) and repeat (B) biopsies of the prostate. Boxed areas represent the 25th and 75th percentiles, and error values; error bars represent the 10th and 90th percentiles.
Figure 3
Figure 3
Association between the tumor‐associated macrophage count and pathological results in patients who underwent repeat biopsies of the prostate. Boxed areas represent the 25th and 75th percentiles, and error values; error bars represent the 10th and 90th percentiles.
Figure 4
Figure 4
Association between the macrophage scavenger receptor count and pathological results in patients who underwent repeat biopsies of the prostate. Boxed areas represent the 25th and 75th percentiles, and error values; error bars represent the 10th and 90th percentiles.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96. - PubMed
    1. Partin AW, Oesterling JE. The clinical usefulness of prostate‐specific antigen: update 1994. J Urol 1994; 152: 1358–68. - PubMed
    1. Kirby SR, Christmas TJ, Brawer MK. Prostate Cancer. London: Mosby, 2001.
    1. Djavan B, Zlotta A, Remzi M et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000; 163: 1144–8. - PubMed
    1. O’Dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000; 55: 553–9. - PubMed

Publication types

Substances